Regeneron Pharmaceuticals to Acquire 23andMe for $256 Million Out of Bankruptcy

Overview

A summary of the key points of this story verified across multiple sources.

Regeneron Pharmaceuticals has announced its acquisition of 23andMe in a bankruptcy auction for $256 million. The firm intends to safeguard customer data while utilizing the vast genetic information for drug discovery. This acquisition ensures the continuation of 23andMe's services and adheres to established privacy protections amidst consumer concerns following the company's financial troubles. The deal, subject to bankruptcy court approval, reflects Regeneron's commitment to ethical data use and advancements in genetics for public health benefits.

Written using shared reports from

4 sources

Report issue

Analysis

Compare how each side frames the story — including which facts they emphasize or leave out.

Biotech company Regeneron to buy bankrupt 23andMe for $256M

Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million

How we categorize media bias